ACT-NOW

Data Standard

HISO 10095:2022

Published XX 2022

Contributors

The ACT-NOW (Anti-Cancer Therapy – Nationally Organised Workstreams) data standard was developed by the ACT-NOW Data Specification Working Group (DWG) as listed below.

Chairs: Dr Laird Cameron, Dr Jason Gurney

Project Manager: Alexander Dunn

* Dr Laird Cameron, Medical Oncologist, Auckland DHB and Canopy Cancer Care
* Dr Jason Gurney, Senior Research Fellow and Director, Cancer and Chronic Conditions (C3) Research Group
* Dr Myra Ruka, Clinical Lead Equity, Te Aho o Te Kahu and Advanced Haematology Registrar at Waikato Hospital
* Dr Christopher Jackson, Medical Oncologist, Southern DHB and Mercy Cancer Care
* Dr John Fountain, Manager, Data Monitoring and Reporting, Te Aho o Te Kahu
* Dr Humphrey Pullon, Haematologist, Waikato
* Dr Michelle Vaughan, Medical Oncologist, CDHB, St George’s Cancer Care
* Dr Clinton Lewis, Haematologist, ADHB
* Laura Moughan, Pharmacist, Counties Manukau DHB
* Dr Shaun Costello, Radiation Oncologist, Southern Blood and Cancer Service Dunedin Hospital
* Janette Ngaheu, Haem Nursing / Programme Manager Clinical Equity – Waikato
* Simon Pointer, National Pharmacist, Treatment Quality and Standardisation, Te Aho o Te Kahu
* Alexander Dunn, Project Manager, Data Monitoring and Reporting, Te Aho o Te Kahu
* Kieron Mottley, Business Analyst, Data Monitoring and Reporting, Te Aho o Te Kahu

Te Aho o Te Kahu also undertook significant consultation with cancer health professionals and subject matter experts across the sector and acknowledges the many people and organisations who contributed to the publication of this standard.

Citation: Te Aho o Te Kahu. 2022. *HISO 10095:2022* *ACT-NOW Data Standards.* Wellington: Te Aho o Te Kahu.

Published in XX 2022 by Te Aho o Te Kahu, the Cancer Control Agency
PO Box 5013, Wellington 6140, New Zealand

ISBN XXX-X-XX-XXXXXX-X (online)
HP XX XXXX



This document is available at [teaho.govt.nz](http://www.teaho.govt.nz) and [health.govt.nz](http://www.health.govt.nz)

|  |  |
| --- | --- |
| **CCBY** | This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made. |

Contents

[1 Introduction 1](#_Toc93501275)

[1.1 Purpose 2](#_Toc93501276)

[1.2 Scope 2](#_Toc93501277)

[1.3 Definitions 3](#_Toc93501278)

[1.4 Legislation and regulations 3](#_Toc93501279)

[1.5 Te Tiriti o Waitangi and achieving equity 4](#_Toc93501280)

[1.6 Related specifications 5](#_Toc93501281)

[1.7 SNOMED CT 5](#_Toc93501282)

[1.8 Character sets 6](#_Toc93501283)

[1.9 Medicine concept specification 6](#_Toc93501284)

[1.10 Data element template 7](#_Toc93501285)

[2 Data elements 8](#_Toc93501286)

[2.1 Facility 9](#_Toc93501287)

[2.2 Patient 9](#_Toc93501288)

[2.3 Diagnosis 10](#_Toc93501289)

[2.4 Observation 15](#_Toc93501290)

[2.5 Staging 16](#_Toc93501291)

[2.6 Prognostic scoring 25](#_Toc93501292)

[2.7 Regimen 27](#_Toc93501293)

[2.8 Cycle 33](#_Toc93501294)

[2.9 Administration 37](#_Toc93501295)

[2.10 Tumour specific elements 42](#_Toc93501296)

[3 Adoption and implementation 48](#_Toc93501297)

[3.1 Adoption roadmap 48](#_Toc93501298)

[3.2 Implementation principles 48](#_Toc93501299)

[Appendix A: Additonal SNOMED CT terms 50](#_Toc93501300)

# Introduction

Te Aho o Te Kahu, the Cancer Control Agency is an independent departmental agency that was established to lead and unite efforts to deliver better cancer outcomes for Aotearoa. Te Aho o Te Kahu is responsible for developing and publishing cancer-specific data standards.

The[**New Zealand Cancer Action Plan | Te Mahere mō te Mate Pukupuku o Aotearoa 2019-2029**](https://www.health.govt.nz/publication/new-zealand-cancer-action-plan-2019-2029)provides a pathway to improve cancer outcomes for all New Zealanders with the objectives of building a system that delivers consistent and modern cancer care, equitable cancer outcomes, fewer cancers and better cancer survival, supportive care and end of life care.

The Anti-Cancer Therapy – Nationally Organised Workstreams (ACT-NOW) programme was launched in 2018 with the aim to develop a detailed database of information on patients receiving systemic anti-cancer therapy (SACT) across New Zealand. ACT-NOW engages with the medical oncology, haematology, pharmacist and nursing communities to identify and reduce variation, enhance equity of access and support resource planning.

ACT-NOW is a key deliverable identified in Te Aho’s New Zealand Cancer Action Plan 2019-2029, with guiding principles that include:

1. Identify and understand key equity issues that exist within systemic therapy and that apply to most or all cancer types (for example, equity of access), and how the collection of specific data could support progress against resolving such issues.
2. Focus on the key issues that are relevant across systemic therapy, irrespective of cancer type.
3. Focus on data collected through oncology e-prescribing systems to help guide a pragmatic system with a high probability of successful implementation. This also means avoiding the shoehorning of new data into these systems where it would be more appropriate to collect elsewhere and/or through different Te Aho workstreams.
4. Have key outcome measures such as survival, treatment utility, etc, in scope.

The initial phase of this programme includes the development of national regimen definitions to create a solid foundation for the subsequent capture of nationally comparable data. The system for the development, maintenance and publication of regimen definitions is known as the SACT Regimen Library system (SRL) and was launched in February 2021.

The final phase includes development of this ACT-NOW data standard, which will support the establishment of a new systemic therapy national data collection and suite of analytics to guide improvements in equity, clinical quality and resource utilisation.

This document identifies and describes the data elements that should be captured from provider electronic systems and submitted into a national collection when prescribing and treating people living with cancer using systemic anti-cancer therapy. The standard was developed by the ACT-NOW Data Specification Working Group (DWG), guided by ACT-NOW principles of driving equity, clinical quality and efficiency within the context of adult medical oncology and malignant haematology.

The membership of the DWG includes representatives from medical oncology, haematology, oncology pharmacy, oncology nursing, research and equity reporting specialists. DWG’s role is to develop and endorse the ACT-NOW data specification; the set of agreed and prioritised data requirements that are relevant to most/all cancer streams across medical oncology and malignant haematology. DWG would endure beyond this to provide ongoing guidance to the Medical Oncology Working Group (MOWG) or the Haematology Working Group (HWG) on any enhancements or refinements to the specification and on the interpretation of collected data.

## Purpose

This document identifies and describes the data elements that should be captured from provider electronic systems and submitted into a national collection when prescribing and treating people living with cancer using systemic anti-cancer therapy. SACT refers to all anti-cancer drug treatments. This includes chemotherapy, targeted therapies, hormones and other drug therapies.

The standard aims to support Te Aho o Te Kahu and the Ministry of Health’s vision to accelerate the shift to a fully interoperable digital health ecosystem. The Ministry of Health has developed an [Interoperability Roadmap](https://www.health.govt.nz/publication/hiso-100832020-interoperability-roadmap) to support a modern, digitally enabled and data-driven health and disability system to improve equity and pae ora (healthy futures). An interoperable digital health ecosystem relies on the national adoption of data standards and collaboration across the health sector.

Te Aho o Te Kahu, in partnership with the Ministry of Health and health sector, will ensure the standard is reviewed and updated as required through the HISO processes.

## Scope

This document covers data captured by the systemic therapy care team as part of the standard patient treatment planning, delivery and monitoring. It includes data elements that are relevant for adult solid or haematological cancers. The standard aims to leverage the structured data that already exists within oncology e-prescribing systems and therefore should not require significant additional data recording by clinical teams.

The standard does not cover:

* Adolescent and young adult cancer patients (AYA)
* Non-malignant bloods
* Clinical trials
* Patients that are not commencing systemic therapy
* Technical specification requirements for implementation, such as creating the data elements in a physical database system
* Capturing clinician details

## Definitions

The following special terms are used in this document.

| **Term** | **Definition** |
| --- | --- |
| AJCC | The American Joint Committee on Cancer (AJCC) develops evidence-based anatomic staging that supports clinicians in understanding and treatment cancer patients |
| DWG | ACT-NOW Data Specification Working Group |
| ECOG status | The Eastern Cooperative Oncology Group (ECOG) score, also called the WHO or Zubrod score, is a measure of cancer patients’ general wellbeing. The score runs from 0 to 5, with 0 denoting perfect health and 5 death. The measure is used to help assess a patient’s ability to cope with different treatment protocols such as chemotherapy. |
| HISO | The Health Information Standards Organisation is kaitiaki and the governing body for health information standards in New Zealand. HISO provides technical leadership and expert advice to the Ministry of Health and other health agencies on the development and adoption of health information standards. |
| HWG | Haematology Working Group |
| ICD-10-AM | The International Statistical Classification of Diseases and Related Health Problems version 10 – Australian Modification. ICD-10 is a health care classification system, providing a system of diagnostic codes for classifying diseases, including nuanced classifications of a variety of signs, symptoms, abnormal findings, complaints, social circumstances and external causes of injury or disease. |
| ICD-O | The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumour diseases. This classification is widely used by cancer registries to capture the morphology of a tumour. |
| Lead clinician | The clinician who assumes primary responsibility for the patient (subject to change as required). |
| MOWG | Medical Oncology Working Group |
| SNOMED CT | Systematized Nomenclature of Medicine – Clinical Terms is a systematic, computer-processable collection of medical terms that provide definitions and synonyms that cover anatomy, diseases, findings, procedures, microorganisms, substances and so on. It is a consistent way to store, retrieve and aggregate medical data across specialties and sites of care. |
| Tumour group or stream | A group of similar or related cancers, usually categorised according to the bodily system or organ they are associated with (for example, bowel, gynaecological, breast). |

## Legislation and regulations

The following legislation and regulations are relevant to this standard:

* Health Information Privacy Code 2020
* Health Practitioners Competence Assurance Act 2003
* Privacy Act 2020
* Public Records Act 2005
* Health (Retention of Health Information) Regulations 1996.
* [Medicines Act 1981 and Medicines Regulations 1984](https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicines-act-1981).

## Te Tiriti o Waitangi and achieving equity

Te Aho o Te Kahu recognises the central importance of its Te Tiriti o Waitangi obligations, including working in partnership with Māori with a clear focus on achieving equity for Māori in terms of cancer outcomes. A critical factor in meeting Te Tiriti obligations and achieving equity objectives includes forming key relationships to inform the scope and development of this standard.

DWG includes Māori researcher/equity reporting specialist co-chair and haematologist members who are also members of the Hei Āhuru Mōwai Māori Cancer Leadership Aotearoa. This group is working together with Te Aho o Te Kahu on work to help reduce inequities for Māori across the cancer continuum. DWG also includes Waikato DHB’s Programme Manager, Clinical Equity. Also consulted for this standard is He Ara Tāngata, Te Aho o Te Kahu’s Consumer Reference Group to provide the voices of people living with cancer, and their whānau.

A primary focus for the DWG is to understand the key known or potential equity issues that exist within systemic therapy access, provision, and outcomes, and to develop a data standard that will support improvements to these. By enabling data capture that would allow for a deeper understanding of the nature and extent of equity issues, more targeted and effective strategies for addressing these inequities may be developed. This will include specific consideration of how data could achieve improved outcomes or equity for Māori.

With consistent data standards for cancer across the health sector, high-quality data can be used to monitor and audit patient pathways locally, regionally and nationally to support the equitable delivery of care across the pathway and improve cancer outcomes. To achieve this the ACT-NOW standard aims to identify the data required to measure and monitor the following to determine inequity of access to systemic therapy:

* access to systemic treatment
* timing of access (relative to diagnosis)
* types of medicines being accessed (best practice care)
* location of treatment relative to residence (patient mobility)
* all of the above, by stage of disease as acted on by clinician(s)
* all of the above, including privately funded care (to complete the picture of access equity)

## Related specifications

The following documents have been used to develop or are referenced in this standard.

* [New Zealand Cancer Health Information Strategy. Wellington: Ministry of Health](https://www.health.govt.nz/publication/new-zealand-cancer-health-information-strategy)
* [New Zealand Cancer Plan: Better, faster cancer care 2015–2018. Wellington: Ministry of Health](https://www.health.govt.nz/publication/new-zealand-cancer-plan-better-faster-cancer-care-2015-2018)
* [New Zealand Cancer Action Plan 2019–2029 – Te Mahere mō te Mate Pukupuku o Aotearoa 2019–2029.](https://www.health.govt.nz/publication/new-zealand-cancer-action-plan-2019-2029) Revised January 2020. Wellington: Ministry of Health
* **HISO 10080 Systemic Anti-Cancer Therapy Regimen Data Standard.** In development.
* [**HISO 10013:2015 HL7 Standards Endorsement**](https://www.health.govt.nz/publication/hiso-100132015-hl7-standards-endorsement)
* [HISO 10038.0:2017 Preface to the Cancer Data Standards](https://www.health.govt.nz/publication/hiso-1003802017-preface-cancer-data-standards)
* [HISO 10038.1:2011 Interim National Cancer Core Data Definitions Standard](https://www.health.govt.nz/publication/hiso-1003832011-interim-national-cancer-core-data-definitions-standard)
* [**HISO 10038.3:2011 Interim National Cancer Core Data Standard**](https://www.health.govt.nz/publication/hiso-1003832011-interim-national-cancer-core-data-definitions-standard)
* [**HISO 10042 Medication Charting and Medicine Reconciliation Standards**](https://www.health.govt.nz/publication/hiso-10042-medication-charting-and-medicine-reconciliation-standards)
* HISO 10045 Health Provider Identity Standard (draft standard available from standards@health.govt.nz)
* [HISO 10046 Consumer Health Identity Standard](https://www.health.govt.nz/publication/hiso-10046-consumer-health-identity-standard)
* [**HISO 10063:2017 GS1 Standards Endorsement**](https://www.health.govt.nz/publication/hiso-10063-gs1-standards)
* [**HISO 10083:2020 Interoperability Roadmap**](https://www.health.govt.nz/publication/hiso-100832020-interoperability-roadmap)
* [Ministry of Health’s Clinical Coding System code table](https://www.health.govt.nz/nz-health-statistics/data-references/code-tables/common-code-tables/clinical-coding-system-code-table)
* [Overall Treatment Utility](https://blogs.ed.ac.uk/canceroutcomes/overall-treatment-utility/)**.** The University of Edinburgh[[1]](#footnote-1)
* [ISO/IEC 10646:2017 Information technology – Universal Coded Character Set (UCS)](https://www.iso.org/standard/69119.html)

## SNOMED CT

Coded data elements in ACT-NOW regimens use by default the SNOMED CT terminology for clinical information. The concepts making up each value domain are denoted by either the preferred term or a clinically agreed term and are linked to entries in the [SNOMED CT browser](https://browser.ihtsdotools.org/) (use Chrome to access this link). The SNOMED CT concept identifier (SCTID) can be viewed by hovering over the link.

Some data elements are restricted to a definite set of SNOMED CT concepts, while others are more open-ended and allow the user to select from a wider set of concepts, usually within a certain hierarchy or sub-hierarchy for example, the set of all disease concepts.

When new values need to be added to the value set collection, these principles apply:

* Where a suitable SNOMED CT concept exists in the SNOMED CT International Edition it will be used
* If a suitable concept in the SNOMED CT International Edition does not exist, a new concept will be created in the SNOMED CT New Zealand Extension.

Systems should display the SNOMED preferred or clinically agreed term and capture the SNOMED concept identifier accordingly. See the [SNOMED CT Search and Data Entry Guide](https://confluence.ihtsdotools.org/display/DOCSEARCH/SNOMED%2BCT%2BSearch%2Band%2BData%2BEntry%2BGuide) for a guide to building a user-friendly search across the terminology.

The latest [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps), incorporating the SNOMED CT International Edition and released in April and October every year, is the standard distribution. SNOMED CT is free to use in New Zealand and easy to implement. Download and install each release from the [Member Licensing and Distribution Service](https://mlds.ihtsdotools.org/#/landing/NZ?lang=en) or integrate your software with the [SNOMED CT terminology service](https://www.health.govt.nz/our-work/digital-health/digital-health-sector-architecture-standards-and-governance/health-information-standards-0/snomed-ct-terminology-service) provided by the Ministry of Health.

## Character sets

Text data elements must accommodate macrons for te reo Māori and diacritic characters for other commonly used languages. By default, this means using the Unicode Basic Latin, Latin-1 Supplement and Latin Extended A character sets.

[ISO/IEC 10646:2017 Information technology – Universal Coded Character Set (UCS)](https://www.iso.org/standard/69119.html) is the recognised standard. UTF-8 is the recommended character encoding.

## Medicine concept specification

This standard specifies medicines using the New Zealand Medicines Terminology (NZMT) Medicinal Product (MP) concept SCTID and Tall Man lettering[[2]](#footnote-2) preferred term.

Where the MP concept models a medicine that either:

* meets the requirements of the Health Quality & Safety Commission (HQSC) Medication Safety Expert Advisory Group’s [Specify Brand Advice Guidance](https://www.hqsc.govt.nz/our-programmes/medication-safety/publications-and-resources/publication/3421/) or
* the working group has objective evidence that available presentations of the medicine are not interchangeable in oncology practice.

The human readable format displayed to users in software systems will be «MP preferred term» «(Brand Name)».

## Data element template

Data element specifications in this standard conform to the requirements of [ISO/IEC 11179 Information Technology – Metadata Registries (MDR)](https://standards.iso.org/ittf/PubliclyAvailableStandards/index.html).[[3]](#footnote-3)

|  |  |
| --- | --- |
| **Definition** | A statement that expresses the essential nature of the data element and its differentiation from other elements in the data set. |
| **Source standards** | Established data definitions or guidelines relating to the data element. |
| **Data type** | Alphabetic (A)DateDate/timeNumeric (N)Alphanumeric (X)Boolean | **Representational class** | Code, free text, value or identifier.For date and time data types, use full date or partial date. |
| **Field size** | Maximum number of characters | **Representational layout** | The formatted arrangement of characters in alphanumeric elements, for example:* X(50) for a 50-character alphanumeric string
* NNN for a 3-digit number
* NNAAAA for a formatted alphanumeric identifier.
 |
| **Value domain** | The named, enumerated or described set of valid values or codes that are acceptable for the data element.Each coded data element has a specified code set. |
| **Obligation** | Indicates if the data element is mandatory, conditional or optional.**Mandatory** means the data element is required unless an exception process is followed.**Conditional** means the data element is required based on another data element.**Optional** means that the data element is available but is not obligatory. |
| **Guide for use** | Additional guidance to inform the use of the data element. |
| **Verification rules** | Quality control mechanisms that preclude invalid values. |

# Data elements

This section describes the set of core minimum data to be captured to support the recording of anti-cancer drug treatment.

Any electronic prescribing technical solution must be able to capture data for multiple treatment plans based on multiple diagnoses and assessments for the same person.

Each diagnosis must have one or more regimens. Each regimen must have one or more cycles which must have one or more administrations.

Figure 1 gives an overview of these relationships. The subsections that follow provide more detail on the data elements.

Figure 1: Conceptual model



## Facility

Information relating to the health provider.

### Facility ID

|  |  |
| --- | --- |
| **Definition** | The unique identifier for the facility that is providing services associated with the patient’s visit. The facility where the treatment is being delivered. |
| **Source standards** | HISO 10045 Health Provider Identity Standard (draft standard available from standards@health.govt.nz). |
| **Data type** | Alphanumeric | **Representational class** | Identifier |
| **Field size** | 8 | **Representational layout** | FXXNNN-C |
| **Value domain** | A valid HPI Facility ID |
| **Obligation** | Mandatory |
| **Guide for use** | The facility identifier is assigned by the HPI system when the facility record in the HPI is created.* It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* Should be automatically populated via integration between clinical systems.
* F is a constant prefix – all facility identification numbers start with ‘F’.
* X is either an alphabetic or numeric.
* N is a number.
* C is the check digit established using the Modulus 11 system.
 |
| **Verification rules** | A valid HPI FAC identifier. |

## Patient

Information relating to the patient.

### Patient details

The format for the following list of patient details is sourced directly from the [HISO 10046 Consumer Health Identity Standard.](https://www.health.govt.nz/publication/hiso-10046-consumer-health-identity-standard) Please use this standard for full definitions and format of these items.

| **Data elements** |  |
| --- | --- |
| National Health Index (NHI) number | Contact details |
| Given name | Street address/address line 1 |
| Family name (surname) | Additional street address/address line 2 |
| Date of birth | Suburb/address line 3 |
| Ethnicity (1–6)\* | Town or city/address line 4 |
| Gender\*\* | Postcode |
| Sex\*\*\* | Domicile code |

\* See [HISO 10001:2017 Ethnicity Data Protocols](https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocols) for the collection and recording of ethnicity data.

\*\* Gender is self-identified (personal preference) and is captured in the patient’s NHI record.

\*\*\* Sex is assigned genetically and is important when determining treatment; therefore, it is a mandatory field. See [HISO 10038.3 Interim National Cancer Core Data Definitions Standard](https://www.health.govt.nz/publication/hiso-1003832011-interim-national-cancer-core-data-definitions-standard) for a definition of this data element.

## Diagnosis

Information relating to the patient diagnosis.

### Date of diagnosis

Collecting the date of diagnosis is critical to assess timeliness of treatment and is not always captured within the NZ Cancer Registry.

|  |  |
| --- | --- |
| **Definition** | The date of the primary diagnosis of cancer for which the patient is receiving systemic therapy. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Mandatory |
| **Guide for use** | Proposed date hierarchyMedical Oncology:1. Date of first (not necessarily definitive procedure) Histology OR Cytology specimen collected.
2. Date Radiology used to make diagnosis was performed
3. Date Tumour markers/bloods taken.
4. Date of Clinical diagnosis.

Haematology:1. Cytology/Histology (for example, bone marrow aspirate or peripheral blood in acute leukaemias, biopsy in lymphomas, biopsy needed in myeloma to confirm diagnosis).
2. Flow cytometry (this is definitely diagnostic for conditions like CLL, and some other low grade B- and T- cell LPDs, sometimes confirms subtype of acute leukaemia).
3. Cytogenetics (this includes FISH) and Molecular (for example, chronic phase CML, JAK+ MPN).
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Primary cancer type

The primary cancer type is key to describing the diagnosis for which treatment is being prescribed, and for contextualising the treatment itself.

|  |  |
| --- | --- |
| **Definition** | The primary cancer type of the diagnosis being treated. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBANote: A SNOMED CT NZ Edition reference set is under development for this element. |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended this data be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
* This must be accompanied with details of the clinical term and the clinical coding system used.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Histology

Histology information is key to describing the diagnosis for which treatment is being prescribed, and for contextualising the treatment itself.

|  |  |
| --- | --- |
| **Definition** | The histologic type of the cancer being treated. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBANote: A SNOMED CT NZ Edition reference set is under development for this element. |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
* This must be accompanied with details of the clinical term and the clinical coding system used.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Laterality

This information is useful for understanding the treatment being provided to a patient receiving chemoradiation.

|  |  |
| --- | --- |
| **Definition** | Laterality describes which side of a paired organ is the origin of the primary cancer being treated. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Left | TBA |
| Right | TBA |
| Bilateral | TBA |
| Unknown | TBA |
| Not Applicable | TBA |

 |
| **Obligation** | Optional |
| **Guide for use** | - |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Grading system

The grading system indicates which grading system is being applied.

|  |  |
| --- | --- |
| **Definition** | The grading system used to grade the cancer. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |

 |
| **Obligation** | Conditional; mandatory if **2.3.6 Grade** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* Different grading systems may be applied to different tumour types.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Grade

The grade of the cancer is key to describing the diagnosis for which treatment is being prescribed, and for contextualising the treatment itself.

|  |  |
| --- | --- |
| **Definition** | The grade of the cancer being treated. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |

 |
| **Obligation** | Optional |
| **Guide for use** | TBA - Cancer type rules for use. |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Grading system version

The version of the grading system used is key for futureproofing the data collection as grading systems may change over time.

|  |  |
| --- | --- |
| **Definition** | Version of the grading system used to grade the cancer being treated. |
| **Source standards** | - |
| **Data type** | TBA | **Representational class** | TBA |
| **Field size** | TBA | **Representational layout** | TBA |
| **Value domain** | TBA |
| **Obligation** | Conditional; mandatory if **2.3.6 Grade** is captured. |
| **Guide for use** | * The data element must be provided to prescribe systemic anti-cancer therapy if a tumour grade is provided.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Valid version of the [grading system](#_Grading_system) recorded. |

### Recurrence type

The recurrence type provides additional detail to describe diagnosis and contextualise treatment.

|  |  |
| --- | --- |
| **Definition** | The type of recurrence being treated. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Local | TBA |
| Regional | TBA |
| Locoregional | TBA |
| Distant | TBA |
| Unknown | TBA |

 |
| **Obligation** | Optional |
| **Guide for use** | - |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Recurrence date

|  |  |
| --- | --- |
| **Definition** | The date of recurrence. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Optional |
| **Guide for use** | - |
| **Verification rules** | A valid date that is less than or equal to the current date. |

## Observation

Information relating to overall patient assessment.

### ECOG status date

|  |  |
| --- | --- |
| **Definition** | The date when the patient’s ECOG status was derived or agreed. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### ECOG status

The ECOG status is critical to contextualise the treatment a person is receiving.

|  |  |
| --- | --- |
| **Definition** | The ECOG status at the start of the regimen as defined by Eastern Cooperative Oncology Group (ECOG). |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | See ‘**ECOG status**’ in **Appendix A: Additional SNOMED CT terms** |
| **Obligation** | Mandatory |
| **Guide for use** | * Useful for comparing ECOG thresholds for the same course of treatment.
* More widespread than KPS (simpler and easier to use).
* Important to tie treatments to outcomes.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

## Staging

This section lists the data elements for capturing the patient’s staging information. Staging systems classify patients with a similar prognosis into groups or stages.

TNM staging is an international staging classification system based on the anatomical site of the primary tumour and the extent of its spread.

* The T (tumour) component refers to the size of the tumour and whether it has spread to surrounding tissues.
* The N (nodes) component describes the presence or absence of tumour in regional lymph nodes.
* The M (metastasis) component refers to the presence or absence of tumour at sites distant from the primary cancer type.

When clinically appropriate, at least one T, N or M needs to be recorded across the clinical and pathological settings (eg a Clinical or Pathological T must be provided, and so on). TNM Staging is only applicable when the diagnosis is for an adult (>16 years of age) non-haematological, non-CNS or non-skin cancer.

Where AJCC is not clinically appropriate, ‘Other staging system’ elements can be recorded.

The staging section in this standard differs slightly from the HISO 10038.4 Cancer Multidisciplinary Meeting Data Standard. This is to reflect the way that staging data is universally captured within the oncology electronic-prescribing systems from which the data will be sourced.

NOTE: Te Aho o Te Kahu (Cancer Control Agency), is undertaking projects to improve the quality and completeness of staging data. This section will be updated to reflect the outcome of this project. Please contact Te Aho o Te Kahu (Cancer Control Agency) for further information by emailing info@teaho.govt.nz.

### Clinical stage

Clinical stage classification **(cTNM)** is based on patient history, physical examination, and any imaging done before initiation of treatment. Imaging study information may be used for clinical staging, but clinical stage may be assigned based on whatever information is available. No specific imaging is required to assign a clinical stage for any cancer site. When performed within this framework, biopsy information on regional lymph nodes and/or other sites of metastatic disease may be included in the clinical classification (source: AJCC 8th edition).

The following data elements identify the key information that helps to determine a suitable treatment option for a patient.

#### TNM: Clinical T stage

|  |  |
| --- | --- |
| **Definition** | Clinical T stage is the coding system used to identify the presence of a primary tumour. It reflects the tumour size and extent of the primary cancer. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid T category code. |
| **Obligation** | Optional |
| **Guide for use** | A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier. |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### TNM: Clinical N stage

|  |  |
| --- | --- |
| **Definition** | Clinical N stage is the coding system used to denote the absence or presence of regional lymph node metastases. It classifies the extent of regional lymph node metastases. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid N category code. |
| **Obligation** | Optional |
| **Guide for use** | A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier. |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### TNM: Clinical M stage

|  |  |
| --- | --- |
| **Definition** | Clinical M stage is the coding system used to record the absence or presence of distant metastases. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid M codes from the current edition of the AJCC TNM *Classification of Malignant Tumours*. |
| **Obligation** | Optional |
| **Guide for use** | A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier. |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Clinical TNM edition used

|  |  |
| --- | --- |
| **Definition** | Staging system edition number used. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |  |
| --- | --- | --- |
| **Clinical term** | **SCTID** |  |
| [American Joint Commission on Cancer, *Cancer Staging Manual*, 7th edition neoplasm staging system](https://browser.ihtsdotools.org/?perspective=full&conceptId1=443830009&edition=MAIN/2021-01-31&release=&languages=en) | 443830009 |  |
| [American Joint Commission on Cancer, *Cancer Staging Manual*, 8th edition neoplasm staging system](https://browser.ihtsdotools.org/?perspective=full&conceptId1=897275008&edition=MAIN/2021-01-31&release=&languages=en) | 897275008 |  |

 |
| **Obligation** | Conditional; mandatory if **2.5.1 TNM: Clinical T,N,M or group stage** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* The nationally agreed standardised classification to use for staging is AJCC TNM *Classification of Malignant Tumours*, 8th edition, January 2017.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Clinical group stage

|  |  |
| --- | --- |
| **Definition** | Clinical group stage is determined from aggregate information on the primary tumour (T), regional lymph nodes (N), and distant metastases (M), as well as any specific prognostic factors for certain cancer types. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid group stage codes. |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* Ensure that the edition number of the classification is recorded.
* Refer to the AJCC TNM *Classification of Malignant Tumours* for coding rules.
* Collect this data element from information provided by the treating doctor and recorded on the patient’s medical record.
* Collection of this data element is conditional on the disease site being listed in the AJCC TNM *Classification of Malignant Tumours*.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Clinical stage date

|  |  |
| --- | --- |
| **Definition** | Clinical stage date is the date of decision to treat. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if **2.5.1 TNM: Clinical T,N,M or group stage** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Pathological stage

Pathological stage classification **(pTNM)** is based on clinical stage information supplemented/modified by operative findings and pathological evaluation of the resected specimens. This classification applies when surgery is performed before initiation of adjuvant radiation or systemic therapy (source: AJCC 8th edition).

The following data elements identify the key information that helps to determine a suitable treatment option for a patient.

#### TNM: Pathological T stage

|  |  |
| --- | --- |
| **Definition** | Pathological T stage is the coding system used to identify the presence of primary tumour. It reflects the tumour size and extent of the primary cancer. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid T category code. |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### TNM: Pathological N stage

|  |  |
| --- | --- |
| **Definition** | Pathological N stage is the coding system used to denote the absence or presence of regional lymph node metastases. It classifies the extent of regional lymph node metastases. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid N category code. |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### TNM: Pathological M stage

|  |  |
| --- | --- |
| **Definition** | Pathological M stage is the coding system used to record the absence or presence of distant metastases. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid M category code. |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* A system should allow the user to select an appropriate TNM category code using the correct SNOMED CT identifier.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Pathological TNM edition used

|  |  |
| --- | --- |
| **Definition** | Staging system edition number used. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **SCTID** | **Clinical term** |
| 443830009 | [American Joint Commission on Cancer, *Cancer Staging Manual*, 7th edition neoplasm staging system](https://browser.ihtsdotools.org/?perspective=full&conceptId1=443830009&edition=MAIN/2021-01-31&release=&languages=en) |
| 897275008 | [American Joint Commission on Cancer, *Cancer Staging Manual*, 8th edition neoplasm staging system](https://browser.ihtsdotools.org/?perspective=full&conceptId1=897275008&edition=MAIN/2021-01-31&release=&languages=en) |

 |
| **Obligation** | Conditional; mandatory if **2.5.2 TNM: Pathological T,N,M or group stage** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems
* The nationally agreed standardised classification to use for staging is AJCC TNM *Classification of Malignant Tumours*, 8th edition, January 2017
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Pathological group stage

|  |  |
| --- | --- |
| **Definition** | Pathological group stage is determined from aggregate information on the primary tumour (T), regional lymph nodes (N), and distant metastases (M), as well as any specific prognostic factors for certain cancer types. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | SNOMED CT identifier that refers to the valid group stage codes. |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* Record the edition number of the classification.
* Refer to the AJCC TNM *Classification of Malignant Tumours* for coding rules.
* Collect this data element from information provided by the treating doctor and recorded on the patient’s medical record.
* Collection of this data element is conditional on the disease site being listed in the AJCC TNM *Classification of Malignant Tumours*.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Pathological stage date

|  |  |
| --- | --- |
| **Definition** | Pathological stage date is the date at time of the surgery (ie, the date the specimen was collected). |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if **2.5.2 TNM: Pathological T,N,M or group stage** is provided. |
| **Guide for use** | This data should be automatically populated via integration between clinical systems. |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Other staging

Where TNM is not used or is not applicable, details of another staging system can be recorded using the following data elements.

The following data elements identify the key information that helps to determine a suitable treatment option for a patient.

#### Other staging system group stage

|  |  |
| --- | --- |
| **Definition** | This describes the anatomical extent of disease at diagnosis based on stage categories of a staging classification other than the standard TNM classification. |
| **Source standards** | - |
| **Data type** | Alphanumeric | **Representational class** | Free text |
| **Field size** | 10 | **Representational layout** | N(10) |
| **Value domain** | Supplementary values:

|  |  |
| --- | --- |
| **Term** | **Code** |
| Not applicable | 8888888888 |
| Unknown | 9999999999 |

 |
| **Obligation** | Optional |
| **Guide for use** | * Applies to all cancer stage groupings where a staging classification other than the standard TNM classification is used. A separate data element captures TNM stage grouping.
* Record valid stage grouping codes from the current edition of the appropriate staging source for the cancer.
 |
| **Verification rules** |  |

#### Other staging system

|  |  |
| --- | --- |
| **Definition** | Staging classification system other than TNM. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |  |
| --- | --- | --- |
| **Clinical term** | **SCTID** |  |
| [FIGO staging system of gynaecological malignancy](https://browser.ihtsdotools.org/?perspective=full&conceptId1=254383006&edition=MAIN/2021-01-31&release=&languages=en) | 254383006 |  |
| Chronic Lymphocytic Leukaemia CLL International Prognostic Index (CLL-IPI) | 1149100002 |  |
| Binet Staging Classification for Chronic Lymphocytic Leukaemia |  1149099005 |  |
| [Breslow system for melanoma staging](https://browser.ihtsdotools.org/?perspective=full&conceptId1=385346008&edition=MAIN/2021-01-31&release=&languages=en) | 385346008 |  |
| Rai staging system for Chronic Lymphocytic Leukaemia | 1149131009 |  |
| [Ann Arbor lymphoma staging system](https://browser.ihtsdotools.org/?perspective=full&conceptId1=254372002&edition=MAIN/2021-01-31&release=&languages=en) | 254372002 |  |
| International Staging System (ISS) for myeloma | 1149162008 |  |
| Revised International Staging System (R-ISS) for myeloma | 1149163003 |  |
| Australian Clinico-pathological Staging (ACPS) system for colorectal cancer | 1149164009 |  |
| [Other](https://browser.ihtsdotools.org/?perspective=full&conceptId1=74964007&edition=MAIN/2021-01-31&release=&languages=en) | 74964007 |  |
| [Unknown](https://browser.ihtsdotools.org/?perspective=full&conceptId1=261665006&edition=MAIN/2021-01-31&release=&languages=en) | 261665006 |  |

Note**:** This list will be revised in a future review. |
| **Obligation** | Conditional; mandatory if **2.5.3 Other staging system group stage** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* TNM staging is not applicable to all tumour sites. Staging is of limited use in some cancers, for example, haematological malignancies. In these cases, use the most appropriate classification system.
* Use the current edition of each staging scheme.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Other staging system version

|  |  |
| --- | --- |
| **Definition** | Version number of staging classification system other than TNM. |
| **Source standards** | - |
| **Data type** | Alphanumeric | **Representational class** | Free text |
| **Field size** | 10 | **Representational layout** | N(10) |
| **Value domain** | Number, 1–87

|  |  |
| --- | --- |
| **Term** | **Code** |
| Not applicable | 88 |
| Unknown edition | 99 |

 |
| **Obligation** | Conditional; mandatory if **2.5.3 Other staging system group stage** is provided. |
| **Guide for use** | Record the version number of the staging system used to stage this diagnosis of cancer. |
| **Verification rules** | A valid version of the [Other staging system](#_Other_staging_system) recorded. |

#### Other staging system stage date

|  |  |
| --- | --- |
| **Definition** | The date when the patient’s overall cancer stage was derived or agreed. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if **2.5.3 Other staging system group stage** is provided. |
| **Guide for use** | - |
| **Verification rules** | A valid date that is less than or equal to the current date. |

## Prognostic scoring

Information relating to prognostic scoring.

Prognostic scoring is critical in describing the cancer diagnosis for most haematological cancers and some solid tumours.

### Prognostic score

|  |  |
| --- | --- |
| **Definition** | The prognostic score on which the cancer treatment is being prescribed. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |

 |
| **Obligation** | Optional |
| **Guide for use** | * TBA
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Prognostic score date

|  |  |
| --- | --- |
| **Definition** | The date when the patient’s prognostic score was derived or agreed. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if **2.6.2 Prognostic score** is provided. |
| **Guide for use** | This data should be automatically populated via integration between clinical systems. |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Prognostic scoring edition

|  |  |
| --- | --- |
| **Definition** | The edition of the prognostic scoring system. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
| TBA | TBA |
|  |  |

 |
| **Obligation** | Conditional; mandatory if **2.6.2 Prognostic score** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Prognostic scoring system

|  |  |
| --- | --- |
| **Definition** | The prognostic scoring system used. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Nottingham prognostic index | 414879002 |
| IPI- International Prognostic Index | 716567001 |
| Follicular Lymphoma International Prognostic Index | 708736003 |
| MIPI - Mantle Cell Lymphoma International Prognostic Index | 763236005 |
| CLL-IPI - Chronic Lymphocytic Leukemia International Prognostic Index | 1149100002 |
| TBA | TBA |
|  |  |

 |
| **Obligation** | Conditional; mandatory if **2.6.2 Prognostic score** is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

## Regimen

Information relating to a patient’s treatment plan.

### SRL regimen code

This data element is critical for linking the regimen a patient is receiving back to the [SACT Regimen Library (SRL)](https://nzf.org.nz/regimens?preview=true).

|  |  |
| --- | --- |
| **Definition** | The SACT Regimen Library ID of the regimen a person is receiving. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | [SACT Regimen Library (SRL)](https://nzf.org.nz/regimens?preview=true) |
| **Obligation** | Conditional; mandatory if a [SRL regimen](https://nzf.org.nz/regimens?preview=true) is provided. |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Regimen ID

This data element details the identifier of the regimen used in the treatment where an SRL regimen is not available/provided, and a local unique identifier is used.

|  |  |
| --- | --- |
| **Definition** | Local unique ID of the regimen. |
| **Purpose** | Records the regimen used in the treatment. |
| **Source standards** | - |
| **Data type** | Alphanumeric | **Representational class** | Identifier |
| **Field size** | TBA | **Representational layout** | X(TBA) |
| **Value domain** | As defined by the local system |
| **Obligation** | Mandatory  |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** |  |

### Regimen name

The regimen name is critical for describing the treatment a patient is receiving.

|  |  |
| --- | --- |
| **Definition** | The name of the regimen/careplan. |
| **Source standards** |  |
| **Data type** | Alphanumeric | **Representational class** | Free text |
| **Field size** | TBA | **Representational layout** | X(TBA) |
| **Value domain** | Valid name assigned from the [SACT Regimen Library](https://nzf.org.nz/regimens?preview=true) or the name defined by the local system. |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* If a SACT Regimen Library (SRL) regimen is used, then this field should reflect the exact SRL regimen name. <https://nzf.org.nz/regimens?preview=true>
 |
| **Verification rules** | For SRL regimens, must be the name assigned to the SRL regimen ID. |

### Treatment intent

The treatment intent characterises the expectation of whether treatment is either curative or palliative.

|  |  |
| --- | --- |
| **Definition** | The intent of the treatment regimen.  |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Adjuvant | 373846009 |
| Neo-adjuvant | 373847000 |
| [Curative](https://browser.ihtsdotools.org/?perspective=full&conceptId1=373808002&edition=MAIN/2021-01-31&release=&languages=en) | 373808002 |
| [Palliative](https://browser.ihtsdotools.org/?perspective=full&conceptId1=363676003&edition=MAIN/2021-01-31&release=&languages=en) | 363676003 |
| Supportive | 399707004 |

 |
| **Obligation** | Mandatory, optional for haematology primary cancer types. |
| **Guide for use** | - |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Clinical trial flag

The clinical trial flag will provide valuable information on understanding access to clinical trials.

|  |  |
| --- | --- |
| **Definition** | Indicates whether the regimen is a clinical trial |
| **Source standards** | - |
| **Data type** | Boolean | **Representational class** | N/A |
| **Field size** | 1 | **Representational layout** | N(1,0) |
| **Value domain** |

|  |  |
| --- | --- |
| 1 | **Yes.** The regimen is a clinical trial |
| 0 | **No.** The regimen is not a clinical trial |

 |
| **Obligation** | Optional |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* It is acknowledged that not all clinical trial data is captured within existing electronic systems.
 |
| **Verification rules** | Valid value only |

### Regimen complete flag

|  |  |
| --- | --- |
| **Definition** | Indicates whether the full regimen has been completed by the patient. |
| **Source standards** | - |
| **Data type** | Boolean | **Representational class** | N/A |
| **Field size** | 1 | **Representational layout** | N(1,0) |
| **Obligation** |

|  |  |
| --- | --- |
| 1 | **Yes.** The full regimen was completed by the patient |
| 0 | **No.** The full regimen was not completed by the patient |

 |
| **Guide for use** | Mandatory |
| **Verification rules** | * This data should be automatically populated
 |
|  | Valid value only |

### Discontinue date

Capturing the date the regimen was discontinued is important to understand variation in treatment discontinuation rates.

|  |  |
| --- | --- |
| **Definition** | Date the regimen was discontinued |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if regimen has been completed or discontinued |
| **Guide for use** | - |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Discontinue reason

Information relating to reasons for treatment discontinuation.

This information is important to understand variation in treatment discontinuation rates and reasons.

#### Overall discontinue reason

|  |  |
| --- | --- |
| **Definition** | The reason the regimen was discontinued |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | See ‘**Overall discontinue reason’** in **Appendix A: Additional SNOMED CT terms** |
| **Obligation** | Conditional; mandatory if **2.7.4 Discontinue date** is provided. |
| **Guide for use** | - |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Discontinue reason due to patient factors

A key objective of ACT-NOW is to identify barriers to access and reasons for treatment discontinuation. Patient factors can play a key role in this and capturing data on patient factors has been identified as an ideal.

|  |  |
| --- | --- |
| **Definition** | The patient factors resulting in treatment discontinuation. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | See ‘**Overall discontinue reason due to patient factors’** in **Appendix A: Additional SNOMED CT terms** |
| **Obligation** | Optional |
| **Guide for use** | * Tier 2 of a discontinue reason selection.
* Multiple options can be selected.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Discontinue reason due to toxicity type

A key objective of ACT-NOW is to identify reasons for treatment discontinuation. Toxicities can play a key role in this and capturing toxicity data has been identified as an ideal.

|  |  |
| --- | --- |
| **Definition** | Toxicities resulting in treatment discontinuation. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | See ‘**Overall discontinue reason due to toxicity type’** in **Appendix A: Additional SNOMED CT terms** |
| **Obligation** | Optional |
| **Guide for use** | * Tier 2 of a discontinue reason selection.
* Multiple options can be selected.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Number of cycles administered

Collecting details about the number of cycles administered in a regiment is important to understand variation in practice.

|  |  |
| --- | --- |
| **Definition** | The number of cycles administered in a regimen. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Required |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid value |

### Disease response

Capturing information on the disease response will provide meaningful yet simple outcomes data for curative treatments.

|  |  |
| --- | --- |
| **Definition** | Disease response category for curative treatments. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Complete response | TBA |
| Not complete response | TBA |
| No response | TBA |
| Partial response | TBA |
| TBA | TBA |
|  |  |

 |
| **Obligation** | Conditional; mandatory if **2.7.1 Treatment intent** value **‘Curative’** is provided. |
| **Guide for use** | - |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Date of completion

|  |  |
| --- | --- |
| **Definition** | The date the planned treatment regimen was completed. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional, Mandatory if the regimen has been completed |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

## Cycle

Information relating to a cycle, the period of chemotherapy treatment given according to a specific schedule.

The cycle number, length, start date, end date and last administration date are used as mechanisms to link the regimen details to the administration details.

### Cycle number

|  |  |
| --- | --- |
| **Definition** | The sequential cycle number within the regimen |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid value greater than zero |

### Cycle length

|  |  |
| --- | --- |
| **Definition** | The intended length of the cycle in a regimen. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3  | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid value |

### Cycle start date

|  |  |
| --- | --- |
| **Definition** | The date the cycle of treatment starts. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Cycle end date

|  |  |
| --- | --- |
| **Definition** | The date the cycle of treatment ends. |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is greater than or equal to the [Cycle start date](#_Cycle_start_date) and less than or equal to the current date. |

### Last administration date

|  |  |
| --- | --- |
| **Definition** | The date of the last administration during the corresponding cycle (for orals this is the last prescription date). |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Mandatory |
| **Guide for use** | * This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | A valid date that is less than or equal to the current date. |

### Dose adjustment reason

Capturing the reason for adjustments is necessary to understand variation in dosing/dose adjustments.

|  |  |
| --- | --- |
| **Definition** | Reason for dose adjustments that apply to a cycle. |
| **Source standards** | - |
| **Data type** | Numeric  | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | See ‘**Dose adjustment reason**’ in **Appendix A: Additional SNOMED CT terms** |
| **Obligation** | Conditional; mandatory if all **2.9.4 Prescribed dose** values and **2.9.2 Administered dose values** for a **2.9.3 Medicine ID** in the cycle differ by the same amount |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems if dose adjustments are made at the regimen or cycle level.
 |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Body Surface Area (BSA)

Knowing the body surface area of a patient at the start of the cycle will provide valuable information to understand variation in dose-capping.

|  |  |
| --- | --- |
| **Definition** | The BSA at the start of the cycle in metres squared. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3  | **Representational layout** | N.NN |
| **Value domain** | Metres squared (m2) |
| **Obligation** | Mandatory depending on regimen |
| **Guide for use** | *Note: TBA if BSA should be recorded to at least one decimal place.** Neither the word ‘metres squared’ nor the abbreviation ‘m2’ should be included in the value of this data element.
 |
| **Verification rules** | Value greater than zero. |

### Weight

Capturing the weight of a patient at the time of encounter is a Health and Disability Commissioner (HDC) requirement.

|  |  |
| --- | --- |
| **Definition** | The measured weight of the patient at the time of the encounter. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 5 | **Representational layout** | NNN.N |
| **Value domain** | Kilograms |
| **Obligation** | Optional |
| **Guide for use** | * Record weight to one decimal place.
* Neither the word ‘kilograms’ nor the abbreviation ‘kg’ should be included in the value of this data element.
 |
| **Verification rules** | Value greater than zero. |

### Creatinine clearance

For some regimens, creatinine clearance is critical to inform/contextualise dosing.

|  |  |
| --- | --- |
| **Definition** | Creatinine clearance used to prescribe the drug |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 5 | **Representational layout** | N(5) |
| **Value domain** | An integer |
| **Obligation** | Optional |
| **Guide for use** | * TBA, unit of measure
 |
| **Verification rules** | Value greater than zero. |

### Creatinine clearance date

The date the creatinine clearance sample was obtained.

|  |  |
| --- | --- |
| **Definition** | Date on which the creatinine clearance was measured |
| **Source standards** | - |
| **Data type** | Date | **Representational class** | Full date |
| **Field size** | 8 | **Representational layout** | YYYYMMDD |
| **Value domain** | Valid date |
| **Obligation** | Conditional; mandatory if **2.8.8 Creatinine clearance** is provided. |
| **Guide for use** | - |
| **Verification rules** | A valid date that is less than or equal to the current date. |

## Administration

Information relating to treatment administration to a patient.

The data elements identified in this section are key to providing an understanding of the treatment information.

### Cycle day

|  |  |
| --- | --- |
| **Definition** | The day in a cycle a dose is administered. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3  | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Value greater than zero. |

### Medicine name

|  |  |
| --- | --- |
| **Definition** | The name of the medicine being administered. |
| **Source standards** | NZ Medicines Terminology |
| **Data type** | Alphanumeric | **Representational class** | Free text |
| **Field size** | TBA | **Representational layout** | X(TBA) |
| **Value domain** | Must be a valid NZ Medicines Terminology medicine |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
* Captured when a drug is administered.
 |
| **Verification rules** | Must be the name assigned to the [Medicine ID](#_Medicine_ID). |

### Medicine ID

|  |  |
| --- | --- |
| **Definition** | The unique ID of the medicine administered. |
| **Source standards** | HISO 10024.1:2018 New Zealand Universal List of Medicines |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | NZMT TPUU SCTID |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
* Captured when a drug is administered.

This data element records the [New Zealand Medicines Terminology](https://view.nzmt.org.nz/) (NZMT) identifier for the specific Trace Product Unit of Use (TPUU)TPUU identifies a specific vaccine, its does form and strength – for example an injectable unit does of a given product.TPUU code can be used to lookup the trade product name in the [NZ Universal List of Medicines](https://info.nzulm.org.nz/) (NZULM) and the associated non-proprietary Medicinal Product Unit of Use (MPUU) details, which include does form and strength.MPUU, in turn, is linked to non-proprietary Medical Product (MP) entities in the NZMT and from there to the SNOMED CT The codes used to identify the different NZMT entity types are all SNOMED CT identifiers (SCTIDs). |
| **Verification rules** | Must be identifier assigned to the [Medicine name](#_Medicine_name). |

### Prescribed dose

|  |  |
| --- | --- |
| **Definition** | The dose according to the selected regimen/cycle. |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3  | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Valid value greater than zero. |

### Prescribed dose unit

|  |  |
| --- | --- |
| **Definition** | The dose unit according to the selected regimen/cycle prescribed. |
| **Source standards** | HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard |
| **Data type** | Numeric  | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | Valid code from ‘**Dose unit**’ in **5.2.6 HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard** |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Validation rules** | Must be an active SNOMED CT concept. |

### Administered dose

|  |  |
| --- | --- |
| **Definition** | The administered dose.  |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3 | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Value greater than zero. |

### Administered dose unit

|  |  |
| --- | --- |
| **Definition** | The unit of measure used for a single dose when the medication was administered to a patient.  |
| **Source standards** | HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard |
| **Data type** | Numeric  | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | Valid code from ‘**Dose unit**’ in **5.2.6 HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard** |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy
* This data should be automatically populated via integration between clinical systems.
 |
| **Validation rules** | Must be an active SNOMED CT concept. |

### Route of administration

|  |  |
| --- | --- |
| **Definition** | The value set the route by which the regimen specifies a medicine is administered to the patient. |
| **Source standards** | HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard |
| **Data type** | Numeric  | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | Valid code from ‘**Route of administration**’ in **5.2.8 HISO 10080:2021 Systemic Anti-Cancer Therapy Regimen Data Standard**  |
| **Obligation** | Mandatory |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Validation rules** | Must be an active SNOMED CT concept. |

### Administration start time

|  |  |
| --- | --- |
| **Definition** | Date and time of administration start |
| **Source standards** | - |
| **Data type** | Date/time | **Representational class** | Full date and time |
| **Field size** | 14 | **Representational layout** | YYYYMMDD HH:MM |
| **Value domain** | Valid date and time |
| **Obligation** | Conditional; mandatory if **2.9.1 Route of administration** value **‘oral administration’** is not provided. |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | This must be a valid date and time that is less than or equal to the current date and time. |

### Administration end time

|  |  |
| --- | --- |
| **Definition** | Datetime of administration end |
| **Source standards** | - |
| **Data type** | Date/time | **Representational class** | Full date and time |
| **Field size** | 14 | **Representational layout** | YYYYMMDD HH:MM |
| **Value domain** | Valid date and time |
| **Obligation** | Conditional; mandatory if **2.9.1 Route of administration** value **‘oral administration’** is not provided. |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | This must be a valid date and time that is greater than or equal to the current date and time. |

### Administration duration

|  |  |
| --- | --- |
| **Definition** | Administration duration in minutes |
| **Source standards** | - |
| **Data type** | Numeric | **Representational class** | Value |
| **Field size** | 3  | **Representational layout** | N(3) |
| **Value domain** | An integer |
| **Obligation** | Conditional; mandatory if **2.9.1 Route of administration** value **‘oral administration’** is not provided. |
| **Guide for use** | * It is recommended that this data element be captured to allow for prescribing of systemic anti-cancer therapy.
* This data should be automatically populated via integration between clinical systems.
 |
| **Verification rules** | Value greater than zero. |

## Tumour specific elements

This lists the details required for specific tumours.

Note: These elements are subject to change following completion of related data specifications in Te Aho o Te Kahu’s Structured Pathology project. Data elements that are needed for publicly available treatments should be mandatory. Prognostic scores should be optional.

### Breast

#### Estrogen Receptor (ER) status

|  |  |
| --- | --- |
| **Definition** | The Estrogen Receptor (ER) status obtained from a patient with breast cancer |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric  | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** |

|  |  |
| --- | --- |
| **Clinical term** | **SCTID** |
| Estrogen receptor negative neoplasm | 441117001 |
| Estrogen receptor positive tumor | 416053008 |

 |
| **Obligation** | Optional |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Progesterone Receptive (PR) status

|  |  |
| --- | --- |
| **Definition** | A code that specifies whether the tumour is progesterone receptive (PR) or not. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### HER2 status

|  |  |
| --- | --- |
| **Definition** | A code for the human epidermal growth factor receptor 2 status of the tumour. |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Lung

#### EGFR

|  |  |
| --- | --- |
| **Definition** | Epidermal Growth Factor Receptor status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### ALK

|  |  |
| --- | --- |
| **Definition** | Anaplastic lymphoma kinase (ALK) status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Bowel

#### MSI

|  |  |
| --- | --- |
| **Definition** | Microsatellite instability status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### BRAF

|  |  |
| --- | --- |
| **Definition** | BRAF mutation status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Head and Neck

#### HPV16

|  |  |
| --- | --- |
| **Definition** | Human papillomavirus 16 status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### CNS – GBM

#### IDH

|  |  |
| --- | --- |
| **Definition** | Isocitrate dehydrogenase status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### Methylation status (variant)

|  |  |
| --- | --- |
| **Definition** | Methylation status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Generic

#### PD1

|  |  |
| --- | --- |
| **Definition** | PD1 protein status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### PD1L

|  |  |
| --- | --- |
| **Definition** | Programmed death-ligand 1 status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Testes

#### LDH

|  |  |
| --- | --- |
| **Definition** | Lactate dehydrogenase status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### AFP

|  |  |
| --- | --- |
| **Definition** | Alpha-fetoprotein status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### HCG

|  |  |
| --- | --- |
| **Definition** | Human chorionic gonadotropin status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

#### IGCCCG

|  |  |
| --- | --- |
| **Definition** | The International Germ Cell Cancer Collaborative Group status |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Renal

*To be determined*

|  |  |
| --- | --- |
| **Definition** |  |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

### Haem

*To be determined*

|  |  |
| --- | --- |
| **Definition** |  |
| **Source standards** | [SNOMED CT New Zealand Edition](https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/new-zealand-snomed-ct-national-release-centre/snomed-ct-subsets-and-maps) |
| **Data type** | Numeric | **Representational class** | Code |
| **Field size** | 18 | **Representational layout** | N(18) |
| **Value domain** | TBA |
| **Obligation** | TBA |
| **Guide for use** |  |
| **Verification rules** | Must be an active SNOMED CT concept. |

# Adoption and implementation

## Adoption roadmap

Te Aho o Te Kahu will lead national adoption of this standard as an element of the ACT-NOW project under the [Cancer Action Plan](https://www.health.govt.nz/publication/new-zealand-cancer-action-plan-2019-2029) 2019-2029.

The adoption roadmap includes:

* publication of approved national standard regimens to <https://nzf.org.nz/regimens>.
* uptake of published regimens by individual cancer units for new patients via manual inclusion into patient care plans created in cancer management software. This supports the capture of data about patient management across the country required by the [Cancer Action Plan](https://www.health.govt.nz/publication/new-zealand-cancer-action-plan-2019-2029).
* addition of new functionality allowing for the electronic import and export of systemic therapy data to and from cancer management systems via FHIR API.
* Development of a national collection and analytics infrastructure to receive systemic therapy data via FHIR API.

## Implementation principles

Key principles for the implementation of this standard include:

* must support capturing and sharing of information electronically while ensuring it is secure and protects patients’ privacy according to the [Privacy Act 2020](https://www.privacy.org.nz/privacy-act-2020/privacy-act-2020/), [Health Information Privacy Code 2020](https://www.privacy.org.nz/privacy-act-2020/codes-of-practice/hipc2020/), and the [HISO 10029:2015 Health Information Security Framework](https://www.health.govt.nz/publication/hiso-100292015-health-information-security-framework).
* must be adaptable to apply new and modified data element requirements when future updates are published.
* should support integration with NHI, HPI, New Zealand Business Number (NZBN) and other master data sources referenced in this document.
* should integrate with other health information systems.
* should use automatically populated information if possible.
* should be used to support any Request for Proposal (RFP) process to select a SACT e-prescribing solution and/or as input into the design and development of this solution.
* should display the SNOMED preferred or clinically agreed term and capture the SNOMED concept identifier accordingly.
* SNOMED CT New Zealand Edition releases are currently published in April and October every year. All client systems should implement each release within three months of the release date. This implementation requirement may be revised in the future if the frequency of releases changes.
* Client system implementations of SNOMED CT New Zealand Edition should have the capability of processing data from previous versions of SNOMED CT.

# Appendix A: Additonal SNOMED CT terms

These are the SNOMED CT data domains (range of allowable options for a particular data element) for selected items in this standard. Both the SNOMED CT clinical term and identifier are presented. Any system should capture and submit to a national collection the clinical term, the associated code and the SNOMED CT version, but only the clinical term should be visible to users.

If a SNOMED CT code has not been provided, a suitable code either does not currently exist or code choices for the domain option are still under development. These will be added later. In this document, these entries are shown as TBA (to be advised). Reference sets for the below tables will be developed and included in a future release of the SNOMED CT New Zealand edition.

#### ECOG status

| **Clinical term** | **SCTID** |
| --- | --- |
| [ECOG performance status – grade 0](https://browser.ihtsdotools.org/?perspective=full&conceptId1=425389002&edition=MAIN/2021-01-31&release=&languages=en)(Fully active, able to carry on all pre-disease performance without restriction) | 425389002 |
| [ECOG performance status – grade 1](https://browser.ihtsdotools.org/?perspective=full&conceptId1=422512005&edition=MAIN/2021-01-31&release=&languages=en)Restricted in physically strenuous activity but ambulatory and can carry out work of a light or sedentary nature (for example, light housework, office work) | 422512005 |
| [ECOG performance status – grade 2](https://browser.ihtsdotools.org/?perspective=full&conceptId1=422894000&edition=MAIN/2021-01-31&release=&languages=en)(Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50 percent of waking hours) | 422894000 |
| [ECOG performance status – grade 3](https://browser.ihtsdotools.org/?perspective=full&conceptId1=423053003&edition=MAIN/2021-01-31&release=&languages=en)(Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours)) | 423053003 |
| [ECOG performance status – grade 4](https://browser.ihtsdotools.org/?perspective=full&conceptId1=423237006&edition=MAIN/2021-01-31&release=&languages=en)(Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair) | 423237006 |
| [ECOG performance status – grade 5](https://browser.ihtsdotools.org/?perspective=full&conceptId1=423409001&edition=MAIN/2021-01-31&release=&languages=en)(Dead) | 423409001 |

#### Overall discontinue reason

| **Clinical term** | **SCTID** |
| --- | --- |
| Toxicity | TBA |
| Disease progression | TBA |
| Patient factors | TBA |
| Treatment complete | TBA |
| Care plan change  | TBA |
| Change of provider | TBA |
| Comorbidity (includes infection) | TBA |
| Deceased | TBA |
| Covid 19 | TBA |
| Unable to contact patient | TBA |

#### Discontinue reason due to patient factors

| **Clinical term** | **SCTID** |
| --- | --- |
| Cost of drug | TBA |
| Travel barriers to accessing care | TBA |
| Other financial reason | TBA |
| Patient pursuing other treatment | TBA |
| Lack of psychosocial support | TBA |
| Lack of clinical support | TBA |
| Insufficient perceived benefit of treatment by patient | TBA |
| Not clarified with patient | TBA |

#### Discontinue reason due to toxicity type

| **Clinical term** | **SCTID** |
| --- | --- |
| Fatigue (drop in PS) | TBA |
| Diarrhoea | TBA |
| Nausea / vomiting | TBA |
| Neuropathy | TBA |
| Stomatitis (=oral mucositis) | TBA |
| Skin (rash, hand foot) | TBA |
| Allergy | TBA |
| Infection | TBA |
| Pulmonary | TBA |
| Cardiac | TBA |
| Vascular | TBA |
| Liver function | TBA |
| Renal function | TBA |
| Hearing | TBA |

#### Dose adjustment reason

| **Clinical term** | **SCTID** |
| --- | --- |
| Rounding | TBA |
| Age/Frailty | TBA |
| Weight change | TBA |
| Dose-capped | TBA |
| Adjusted Bodyweight | TBA |
| Performance status | TBA |
| Diarrhoea | TBA |
| Nausea / vomiting | TBA |
| Neuropathy | TBA |
| Fatigue | TBA |
| Stomatitis | TBA |
| Skin (rash, hand foot) | TBA |
| Allergy | TBA |
| Neutropenia | TBA |
| Thrombocytopenia | TBA |
| Liver function | TBA |
| Renal function | TBA |
| Lung toxicity | TBA |
| Hearing | TBA |
| Anaemia | TBA |
| Constipation | TBA |
| metabolic/mineral abnormality | TBA |
| Infection | TBA |
| Cardiac Toxicity | TBA |
| Other Toxicity | TBA |

1. Creative Commons Attribution-ShareAlike CC BY-SA 4.0. [↑](#footnote-ref-1)
2. Tall Man lettering is an error–prevention strategy to reduce the risk of look-alike and sound-alike medicine name confusion and errors. It uses selective capitalisation to make similar looking medicine names easier to differentiate. [↑](#footnote-ref-2)
3. See <https://standards.iso.org/ittf/PubliclyAvailableStandards/index.html> [↑](#footnote-ref-3)